Home     Font Size: 1  2  3    Send to a Friend       search

News & Events

European Regulatory Agency Grants Orphan Status to Morphotek's Farletuzumab and MORAb-009

April 16, 2008

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Corporation of North America 201-746-2241...

+ Read the Article

Morphotek Signs Exclusive Licensing Agreement for Anti-Cancer Antibody

March 6, 2008

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Inc. 201-746-2241 judee_shuler@eisai.com ...

+ Read the Article

Morphotek Announces Collaborative Research Agreement with Ludwig Institute for Cancer Research

January 16, 2008

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Inc. 201-746-2241 judee_shuler@eisai.com ...

+ Read the Article

Morphotek Announces Agreement for the Development of Antibodies to Treat Prostate Cancer

January 9, 2008

Contact: Philip Sass Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Inc. 201-746-2241 judee_shuler@eisai.com Bryan ...

+ Read the Article

Morphotek Announces Initiation of MORAb-009 Phase II Study in First Line Treatment of Pancreatic Cancer

January 8, 2008

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Inc. 201-746-2241 judee_shuler@eisai.com ...

+ Read the Article

Research Uncovers Molecular Function of Endosialin Target of MORAb-004, Anti-Angiogenic Antibody Being Evaluated for Cancer, Neovascular Disease

November 20, 2007

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Bryan Evans Reverb—DBC 215-957-0300...

+ Read the Article

Morphotek Receives U.S. Patent Regarding Methods for Generating Genetically Altered Antibodies with Enhanced Affinity and Antibodies Produced by them

November 19, 2007

Contact: Philip M. Sass Morphotek, Inc. 610-423-6100 info@morphotek.com Bryan Evans Reverb—DBC 215-957-0300...

+ Read the Article

Morphotek Receives $2.7M in Funding from the National Institute of Allergy and Infectious Diseases to Develop Therapeutic Antibodies against Biowarfare Agents

October 4, 2007

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.comBryan Evans Reverb—DBC 215-957-0300 ...

+ Read the Article

Morphotek Receives $2.3M in Funding from the U.S. Department of Defense to Develop Therapeutic Antibodies Against Biowarfare Agents

September 18, 2007

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.comBryan Evans Reverb—DBC 215-957-0300 ...

+ Read the Article

Morphotek CEO Named Ernst & Young Entrepreneur Of The Year® 2007 Award Winner in Greater Philadelphia Region

June 27, 2007

For Immediate Release Morphotek CEO Named Ernst & Young Entrepreneur Of The Year® 2007 Award Winner in...

+ Read the Article
Go to Page: 1 2 3 4 5 6 7 8

Results per page   10  25  50



©2005 Morphotek Inc. | 210 Welsh Pool Road | Exton, PA 19341 | (610) 423-6100                        Privacy Policy | Site Map | Contact Us